Omnipod 5 sustains glycemic gains over 12 months in adults

This extension study confirms durable time-in-range and HbA1c improvements with a tubeless automated insulin delivery system in French adults with Type 1 diabetes, informing counseling on long-term device persistence.

Omnipod 5automated insulin deliveryAIDinsulin pumpcontinuous glucose monitoringType 1 diabetestime in rangeHbA1cextension studyInsuletDexcom G6diabetes technology Endocrinology / Diabetes / Obesity

Background Information

The Omnipod 5 System enhances and sustains diabetes control long-term.

Understanding the long-term effectiveness of automated insulin delivery systems is crucial for improving management in adults with type 1 diabetes (T1D). Time in target glucose range increased by 17.9% (p < 0.0001), and HbA1c decreased from 8.33% to 7.18% over 12 months with the Omnipod 5 System. Results indicate sustained efficacy and safety of the Omnipod 5 System, supporting its use as a long-term option for T1D management in France. Omnipod 5 System shows sustained, improved glycemic control over 12 months in adults with T1D.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Renard E, Weinstock RS, Penfornis A, Riveline JP, Thivolet C, Ly TT, OP5‐003 Research Group

Citation: Renard E, Weinstock RS, Penfornis A, et al. Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial. Endocrinology, diabetes & metabolism. 2026;9(5):e70321. doi:10.1002/edm2.70321

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →